Veru (NASDAQ:VERU) announced that it has reached its targeted full enrollment of 150 patients for its Phase 2b QUALITY clinical trial of enobosarm, in combination with semaglutide, aimed at muscle preservation for high-quality weight loss in patients undergoing treatment with a GLP-1 receptor agonist.
The clinical study, designed to evaluate the safety and efficacy of enobosarm as a treatment to preserve muscle and augment fat loss in patients with sarcopenic obesity or overweight elderly patients receiving semaglutide, is being conducted at 14 sites throughout the U.S. Topline data for the primary endpoint, which is total lean body mass, is expected in January 2025.
“Over the past quarter, we presented data at numerous prestigious scientific conferences and meetings, highlighting enobosarm’s benefits in muscle preservation, physical function improvement, and safety as demonstrated in five previous enobosarm muscle clinical trials,” said Mitchell Steiner, MD, chairman and CEO of Veru in a statement. “We are enthusiastic about enobosarm’s potential to address the muscle loss and physical function challenges in our Phase 2b QUALITY clinical trial.”
